--(BUSINESS WIRE)--Biogen Inc. (Nasdaq ... STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine.

Pharmaceutical giant AbbVie has inked another collaboration deal with an emerging biotech company as it seeks ways to bulk up its drug ... such as Novo Nordisk and Biogen. The company focuses ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Biogen retains an interest in treating Parkinson’s by targeting LRRK2, with BIIB122, an inhibitor of the protein, remaining in the biotech’s phase 2 pipeline. Finally, Biogen brought an end to ...

Biogen's Q4 2024 earnings showed slight revenue ... targeting amyloid beta ("sticky" clumps of protein, the removal of which has been associated with improvement in a patient's condition) that ...

Biogen (NASDAQ:BIIB) shares traded flat in the premarket on Wednesday after the Alzheimer’s drug developer reported better-than-expected Q4 2024 financials while its full-year outlook ...

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.

Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.

American biotechnology company Biogen (BIIB) expects lower profits in 2025, impacted by a stronger dollar (DX=F, DX-Y.NYB) and competition for its multiple sclerosis (MS) drugs. Despite this ...

Biogen's Q4 adjusted EPS rose 17% to $3.44, beating the $3.35 estimate, with revenue up 3% to $2.46B, exceeding the $2.40B consensus. Biogen expects 2025 revenue to decline mid-single digits as ...

Investors with a lot of money to spend have taken a bullish stance on Biogen BIIB. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...